Get the Stockscreener App
55.68
0.91%
0.55
Supernus Pharmaceuticals Inc stock is traded at $55.68, with a volume of 617.12K.
It is up +0.91% in the last 24 hours and up +15.06% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$55.13
Open:
$55.28
24h Volume:
617.12K
Relative Volume:
0.75
Market Cap:
$3.11B
Revenue:
$665.13M
Net Income/Loss:
$64.50M
P/E Ratio:
48.66
EPS:
1.1442
Net Cash Flow:
$185.87M
1W Performance:
+5.52%
1M Performance:
+15.06%
6M Performance:
+69.40%
1Y Performance:
+63.76%
1-Day Range:
$54.27
$56.12
1-Week Range:
$51.84
$57.65
52-Week Range:
$29.16
$57.65
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
55.55 | 3.09B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
ZTS
Zoetis Inc
|
144.33 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.43 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.39 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.51 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.53 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Statistical indicators supporting Supernus Pharmaceuticals Inc.’s strengthStock Surge & Weekly High Return Stock Opportunities - newser.com
Using data models to predict Supernus Pharmaceuticals Inc. stock movementBuy Signal & Verified Short-Term Plans - newser.com
Long term hold vs stop loss in Supernus Pharmaceuticals Inc.Earnings Overview Summary & Weekly Watchlist for Consistent Profits - newser.com
Supernus Pharmaceuticals (SUPN) Reports Q3: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Why Supernus Pharmaceuticals Inc. stock remains undervaluedJuly 2025 Trade Ideas & Safe Capital Growth Plans - newser.com
Is Supernus Pharmaceuticals Inc. stock near bottom after declineEntry Point & Stepwise Trade Signal Implementation - newser.com
Supernus Pharmaceuticals Inc. stock trendline breakdown2025 Retail Activity & Risk Managed Investment Signals - newser.com
Advanced analytics toolkit walkthrough for Supernus Pharmaceuticals Inc.2025 Support & Resistance & Verified Short-Term Trading Plans - newser.com
Top chart patterns to watch in Supernus Pharmaceuticals Inc.July 2025 Institutional & Fast Momentum Stock Entry Tips - newser.com
Is Supernus Pharmaceuticals Inc. stock attractive after correctionJuly 2025 PostEarnings & Technical Pattern Alert System - newser.com
How to monitor Supernus Pharmaceuticals Inc. with trend dashboardsRisk Management & Smart Swing Trading Techniques - newser.com
What institutional flow reveals about Supernus Pharmaceuticals Inc.Weekly Profit Analysis & High Conviction Buy Zone Alerts - newser.com
Supernus Pharmaceuticals Inc expected to post earnings of 28 cents a shareEarnings Preview - TradingView
Supernus Pharmaceuticals (SUPN): Is the Recent Rally Reflected in Its Valuation? - Sahm
Supernus Pharmaceuticals Hits New 52-Week High of $57.65 - Markets Mojo
Supernus a new buy at BofA on 'underappreciated' CNS assets - MSN
Can Supernus Pharmaceuticals Inc. stock continue upward trendDollar Strength & Fast Entry High Yield Stock Tips - newser.com
How Supernus Pharmaceuticals Inc. stock reacts to Fed rate cutsPortfolio Performance Summary & Short-Term Swing Trade Alerts - newser.com
Sentiment analysis tools applied to Supernus Pharmaceuticals Inc.Market Growth Summary & Fast Gain Swing Trade Alerts - newser.com
Supernus Pharmaceuticals, Inc. (SUPN) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Supernus Pharmaceuticals Hits New 52-Week High of $55.95 - Markets Mojo
Supernus Pharmaceuticals, Inc. (SUPN) Stock forecasts - Yahoo! Finance UK
Supernus Pharmaceuticals Inc Stock Analysis and ForecastQuarterly Earnings Review & Rapid Portfolio Appreciation - earlytimes.in
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo! Finance Canada
Supernus Pharmaceuticals (SUPN) Gains Market Attention with Key CNS Drugs - GuruFocus
Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy - sharewise.com
Can Supernus Pharmaceuticals Sustain Momentum After 13% Jump on Neuroscience Pipeline News? - Yahoo Finance
Supernus Pharmaceuticals Hits New 52-Week High of $53.28 - Markets Mojo
BofA Securities Initiates Supernus Pharmaceuticals at Buy With $65 Price Target - MarketScreener
B of A Securities Initiates Coverage on SUPN with a Buy Rating | - GuruFocus
Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36 - Nasdaq
B of A Securities Initiates Coverage of Supernus Pharmaceuticals (SUPN) with Buy Recommendation - Nasdaq
It’s Clear How Big Money Flows Lift Supernus - Yahoo Finance
Will Supernus Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Selloffs & Safe Entry Point Alerts - Fundação Cultural do Pará
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline - Yahoo Finance
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Supernus Pharmaceuticals Inc Stock (SUPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khattar Jack A. | President, CEO |
Oct 09 '25 |
Sale |
50.57 |
59,900 |
3,029,336 |
1,206,578 |
| NEWHALL CHARLES W III | Director |
Oct 09 '25 |
Sale |
50.77 |
25,000 |
1,269,234 |
104,644 |
1.15%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):